Suppressor of cytokine signaling 6 in cancer development and therapy: Deciphering its emerging and suppressive roles

Zhi Yang1, Shigao Huang2, Lina Zhao2

  • 1Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, 15 West Changle Road, Xi'an, China; Department of Radiation Oncology, General Hospital of Southern Theatre Command of PLA, 111 Liuhua Road, Guang Zhou 510010, China.

Insights

Suppressor of cytokine signaling 6 (SOCS6) is crucial in regulating cancer development by inhibiting key signaling pathways. Reduced SOCS6 expression promotes tumor growth, migration, and resistance to cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Suppressor of cytokine signaling 6 (SOCS6) is a key regulator in the SOCS family, increasingly recognized for its role in cancer.
  • SOCS6 functions in negative feedback loops, attenuating cytokine and receptor tyrosine kinase signaling pathways.
  • Downregulation of SOCS6 is linked to critical tumorigenic processes including uncontrolled cell proliferation, apoptosis evasion, and cancer cell migration.

Purpose of the Study:

  • To review the regulatory mechanisms of SOCS6 across multiple signaling pathways.
  • To elucidate the role of SOCS6 in pathological cancer processes and tumor progression.
  • To discuss the clinical relevance of SOCS6 as a cancer biomarker, in prognosis, and in chemo/radioresistance.

Main Methods:

  • Literature review of SOCS6 regulation and function in cancer.
  • Analysis of SOCS6's inhibitory role in tumor progression pathways.
  • Examination of clinical data regarding SOCS6 in cancer biomarkers, prognosis, and treatment resistance.

Main Results:

  • SOCS6 negatively regulates cytokine and receptor tyrosine kinase signaling cascades.
  • Reduced SOCS6 expression is associated with enhanced cancer cell proliferation, survival, migration, and stemness.
  • SOCS6 plays a significant role in modulating chemoresistance and radioresistance in various cancers.

Conclusions:

  • SOCS6 exhibits potent tumor-suppressive functions by inhibiting oncogenic signaling.
  • Understanding SOCS6 regulation provides insights into cancer development and progression.
  • SOCS6 holds potential as a clinical biomarker and therapeutic target for improving cancer treatment outcomes.

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K